The Cancer Research Institute is proud to announce the newest cohort of Lloyd J. Old STARs! Named in tribute to CRI’s founding scientific and medical director, the Lloyd J. Old STAR Program has allocated $40 million to a total of 32 recipients. Among these, five newly awarded researchers will each receive $1.25 million over five years to drive high-risk, high-reward projects with the potential to transform cancer treatment and advance the frontiers of cancer science. Meet this year’s class of STARs, including Dr. Paul Beavis of University of Melbourne, Peter MacCallum Cancer Centre, Dr. Benjamin Izar of Columbia University, Dr. Stacy Malaker of Yale University, Dr. Yifat Merbl of Weizmann Institute of Science, and Dr. Mark Sellmyer of Penn Medicine, University of Pennsylvania Health System: https://bit.ly/46GE8kk #CancerResearch #Immunotherapy #CancerResearcher
Cancer Research Institute (CRI)
Non-profit Organizations
New York, NY 93,975 followers
Founded in 1953, CRI is the world's leading nonprofit dedicated to funding cancer immunotherapy research.
About us
Founded in 1953, the New York City-based Cancer Research Institute is a nonprofit organization dedicated to extending the lives of cancer patients and reducing cancer-related deaths by fueling the development of smarter, more effective treatments that mobilize our body’s natural immune defenses against all types of cancer. To accomplish this goal, the Cancer Research Institute supports the most critical research, invests in the development of promising new treatments, and unites the efforts of the field’s leaders worldwide. Through this work, Cancer Research Institute is transforming cancer therapy, enabling patients to live longer, healthier lives free from the fear of cancer. For more information visit www.cancerresearch.org.
- Website
-
http://www.cancerresearch.org
External link for Cancer Research Institute (CRI)
- Industry
- Non-profit Organizations
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 1953
- Specialties
- cancer, immunotherapy, nonprofit, immuno-oncology, immunology, and charity
Locations
-
Primary
29 Broadway
Floor 4
New York, NY 10006-3111, US
Employees at Cancer Research Institute (CRI)
Updates
-
In a new study published in Cell Press' Cell Reports, investigators from UCLA Health Jonsson Comprehensive Cancer Center, including CRI Scientific Advisory Council member Dr. Antoni Ribas, reveal how a protein called interferon regulatory factor (IRF1) can "both hinder and help the body's immune response to tumors, depending on which cells the protein is found in." Understand how researchers aim to translate their findings into immunotherapy treatments, and to ultimately improve outcomes for cancer patients: https://bit.ly/3WvxrwC #Immunotherapy #CancerResearch #CancerResearcher
-
Why attend #CICON24? During the four days of CICON, dozens of leaders in immunology and immunotherapy will take part in informative and interesting sessions, or groupings of scheduled presentations. CRI Scientific Advisory Council Associate Director, and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Dr. Elizabeth Jaffee, and 2021 William B. Coley Award recipient Dr. Özlem Türeci of BioNTech SE are set to be two of the conference’s four co-chairpersons. “Whether you are an early-career scientist, trainee, or an expert, this is the place to network if you want to be a part of the discussion,” says Dr. Jaffee. “We have experts who will be talking about the challenges and the progress made in areas of data science, new technologies, and cancer biology.” Learn more: https://bit.ly/3ypeq71 #CancerResearch #Immunotherapy #CancerResearcher
Translating Science into Survival at the 8th Annual CICON Conference - Cancer Research Institute
https://www.cancerresearch.org
-
Act quickly, and submit your abstract for #CICON24 before 11:59 pm ET on August 8! Don't miss this opportunity to showcase your research to a prestigious audience, and to collaborate with colleagues from around the world. Submit your abstract now for the Eighth International Cancer Immunotherapy Conference: Translating Science into Survival, presented by the Cancer Research Institute and the European Network for Cancer Immunotherapy, in conjunction with ENCI partner organizations, CIMT, EATI, NIBIT, and GÉTICA: https://bit.ly/43jiwso #CancerResearch #Immunotherapy #CancerResearcher
-
Did you know? August is National Make-A-Will Month. Generous bequests enable scientists who are funded by the Cancer Research Institute to continue their rigorous immunotherapy research that can benefit countless cancer patients. Learn how you can leave a legacy, and give through a will or a living trust to accelerate groundbreaking cancer immunotherapy research, in our latest blog post: https://bit.ly/3YnQ2NO #FreeWill #MakeAWillMonth #CancerResearch #Immunotherapy
Leaving a Legacy: How Bequests to CRI Drive Immunotherapy Advances - Cancer Research Institute
-
"The reality is that lung cancer isn't just one illness. Everybody has a completely different disease, and they have a completely different immune system that has seen different viruses and bacteria throughout their life. Because of that, we're never going to have a one-size-fits-all immunotherapy treatment for patients," explains CRI Clinical Innovator Dr. Thomas Marron of Icahn School of Medicine at Mount Sinai, "but we are slowly moving to a world in which we will have a more personalized approach...where we'll be identifying up-front which patients will respond best to which therapies." Learn more about the latest developments in cancer immunotherapy research for lung cancer during the Cancer Research Institute's virtual Patient Immunotherapy Summit: https://bit.ly/4bB2kFl #CancerResearch #Immunotherapy #LungCancer #NSCLC #PatientSummit
-
Why does cancer risk skyrocket as we age? Researchers, including former CRI Tech Impact Award recipient, and director of the Icahn Genomics Institute at Icahn School of Medicine at Mount Sinai, Dr. Brian Brown, suggest that the answer could lie within the complex relationship between inflammation and cancer. Inflammaging, a “mash of inflammation and aging,” describes Dr. Brown, is "a newly appreciated factor in the aging process and one that contributes to the higher likelihood of developing cancer in older people.” “There’s an urgency to understand why we become hyper-inflamed as we age, and how we can safely reduce this inflammaging without causing immune suppression,” he says. “We’re getting closer to solving this and it’s going to help us live healthier lives.” More: https://aol.it/4fBUZcb #CancerResearch #CancerResearcher #CancerRisk
Why does cancer risk skyrocket as we age? How ‘inflammaging' is the new tool to end the disease
aol.com
-
Did you know that your donation to the Cancer Research Institute could have twice, or even three times the impact, through your employer's matching gift program? Visit our website to see if your company offers a charitable match, and learn how you can magnify your gift to fund lifesaving discoveries: https://bit.ly/3qJnfoo #CancerResearch #MatchingGift #EmployerMatchingGift
Employer Matching Gifts | Cancer Research Institute
https://www.cancerresearch.org
-
Have you submitted your abstract for #CICON24 yet? The submission portal for abstracts will only remain open until 11:59 pm ET on Thursday, August 8, 2024. Act quickly, and submit your abstract for the Eighth International Cancer Immunotherapy Conference: Translating Science into Survival, presented by the Cancer Research Institute, and European Network for Cancer Immunotherapy, in conjunction with ENCI partner organizations, CIMT, EATI, NIBIT, and GÉTICA: https://bit.ly/43jiwso #CancerResearch #Immunotherapy #CancerResearcher
-
“I've been in remission since September 2021. I feel like I've been blessed that I was able to be on immunotherapy," shares Lenny, who was diagnosed with stage four lung cancer at age sixty two. "I think it’s a game changer.” Hear how Lenny found hope through immunotherapy, and discover more success stories on our website: https://bit.ly/4eV3xub #Immunotherapy #CancerResearch #LungCancer